Mapp Biopharmaceutical's Ebola Drug Production Set for Texas, Possibly North Carolina

Published: Sep 30, 2014

A federal initiative to ensure that the United States can respond to biological threats at home will be put to the test in response to the Ebola outbreak in West Africa.

A Texas site is preparing to manufacture the experimental Ebola drug ZMapp, says Robin Robinson, director of the Biomedical Advanced Research and Development Authority (BARDA), a division within the U.S. Department of Health and Human Services. Robinson adds that Novartis’s (NYSE: NVS) vaccine facility in North Carolina is a possible second site to make the drug. Those sites were developed previously in partnership with a U.S. government effort to establish response centers capable of manufacturing drugs and vaccines in an emergency.

Help employers find you! Check out all the jobs and post your resume.

Back to news